Sun Pharma to market Novartis Exelon® –  gets  another 180 day marketing exclusivity on a first-to-file ANDA with para IV certification

Pharma major Sun Pharmaceutical Industries received the final approval from the US Food and Drug Administration (USFDA) to market the generic version of Novartis Exelon®, rivastigmine tartrate capsules.

These generic rivastigmine capsules are AB-rated equivalent of Novartis Exelon® Capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base).  These strengths of Exelon® have annual sales of approximately USD 200 million in the US

It is primarily used for treating Alzheimer's and Parkinson's diseases. The generic version of rivastgmine tartrate capsules (Exelon) comes in four strengths, 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). Rivastgmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson's disease.